Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Lipari Mining and SpurChain Partner to Tokenize Natural Diamond Production (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Zyversa Therapeutics Inc
ZVSA
Healthcare
Biotechnology
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory...
drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCQB:ZVSA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2024 7:55am
New Press Release - ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.The pathomechanism...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 8:10am
New Press Release - ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTSPhase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of...
read article.
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 06, 2024 9:16am
ZVSA.....trading at $1.78 this a.m
I'll say it now .....All the Chsers have been had....AGAIN !!!
(434)
•••
Iseneschal
X
Comment by
Iseneschal
on Nov 05, 2024 10:40am
RE:ZVSA.....I'd say we get some "sideways action" for a awhile
Well that didn't happen ; ) The support has been broken....as I previously mentioned.....she's done Should have just kept my short position....just watching the action now No position
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 05, 2024 10:24am
ZVSA.....I'd say we get some "sideways action" for a awhile
possible bounce and vol spike If ur in ....use it to sell...currently at $2.60 JMHO
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 05, 2024 10:14am
ZVSA....2 x's tap on the L.O.D....
which is that support line I mentioned Better hold and rally or its done
(434)
•••
Iseneschal
X
Comment by
Iseneschal
on Nov 05, 2024 10:08am
RE:ZVSA.......I have started a short position
Covered short position at $2.69 I'll take that profit any day Might re-enter the short position
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 05, 2024 10:04am
ZVSA.... now let's see if my calculations are correct ; )
Currently trading at ~ $2.82 I see support at $2.61 Vols are declining ....this better hold the support or it's done
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 05, 2024 9:51am
ZVSA.......I have started a short position
at $3.25 ; )
(434)
•••
Iseneschal
X
Comment by
Iseneschal
on Nov 05, 2024 9:38am
RE:ZVSA....On watch list at $2.05
Sold all into the a.m opening strength over $3.00 Cha F'king Ching !!!!!!
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 05, 2024 9:26am
ZVSA...early a.m runner up on NR....big vol & price action
Currently at $2.90 Here is the News Release: ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic
...more
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 29, 2024 11:24am
ZVSA....On watch list at $2.05
Starter position here
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 01, 2024 2:49pm
ZyVersa Therapeutics, Inc. (ZVSA): A Promising Biopharmaceut
https://beyondspx.com/2024/08/01/zyversa-therapeutics-inc-zvsa-a-promising-biopharmaceutical-company-developing-novel-treatments-for-renal-and-inflammatory-diseases/
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 22, 2024 7:47am
New Press Release - ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability.A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 14, 2024 7:53am
New Press Release - ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and cognitive disability, and 1.2 million new cases are diagnosed annually. The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of...
read article.
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >